SI
SILO.US Silo Pharma Inc
- Market cap
- USD 3.69M
- P/E
- -
- P/B
- 0.74x
- ROE
- -44.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SILO.US undervalued?
Graham numberThe Graham number of Silo Pharma Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Silo Pharma Inc fundamental analysis
No fundamental analysis for Silo Pharma Inc yet.
Silo Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-indu…
Full company profileSilo Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Silo Pharma Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | -669K | 847K | 0.00 | 40.6K | 40.9K | 71.3K | 72.1K | 72.1K | 72.1K | 72.1K | - |
| Gross Profit | -669K | 847K | -17.6K | 13.2K | -135K | 66.3K | 66.3K | 66.3K | 66.3K | -814K | -339K |
| Operating Income | -394K | -470K | -594K | -930K | -2.20M | -2.74M | -3.63M | -3.86M | -4.71M | -4.28M | -4.98M |
| EBITDA | 326K | 357K | -952K | -950K | -2.40M | 4.19M | -3.91M | -3.63M | -4.38M | -4.18M | -5.12M |
| Net Income | -1.11M | 357K | -969K | -1.01M | -3.04M | 3.90M | -3.91M | -3.70M | -4.39M | -4.23M | -3.78M |
| EPS | -17 | 5.13 | -15 | -18 | -35 | 2.03 | -1.71 | -1.20 | -18 | -7.57 | -2.17 |
| Balance Sheet | |||||||||||
| Total Assets | 1.30M | 1.64M | 855K | 494K | 1.43M | 10.5M | 11.6M | 7.75M | 7.41M | 7.61M | 8.80M |
| Total Liabilities | 453K | 438K | 448K | 517K | 146K | 1.43M | 1.30M | 1.57M | 2.38M | 1.30M | 351K |
| Shareholders' Equity | 847K | 1.20M | 407K | -22.9K | 1.28M | 9.06M | 10.3M | 6.18M | 5.03M | 6.31M | 8.44M |
| Cash & Short-term Investments | 579K | 295K | 565K | 121K | 1.13M | 10.3M | 11.4M | 7.67M | 7.08M | 6.86M | 8.05M |
| Total Debt | - | - | 22.3K | 61.9K | 18.9K | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -144K | -285K | 273K | -794K | -1.16M | -2.28M | -3.50M | -3.22M | -3.83M | -4.66M | -2.94M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 0.00 | 575K | 8.00 |
| Free Cash Flow | -144K | -285K | 273K | -794K | -1.16M | -2.28M | -3.50M | -3.22M | -3.83M | -4.66M | -2.94M |
| Ratios | |||||||||||
| ROE | -131.5% | 29.6% | -237.9% | - | -237.2% | 43.1% | -37.8% | -59.9% | -87.3% | -67.0% | -44.8% |
| ROA | -85.6% | 21.7% | -113.3% | -205.2% | -212.9% | 37.2% | -33.6% | -47.8% | -59.3% | -55.6% | -43.0% |
| Net Profit Margin | - | 42.1% | - | -2,497.7% | -7,422.5% | 5,477.9% | -5,420.9% | -5,132.6% | -6,092.6% | -5,863.5% | - |
| Debt to Equity | - | - | 0.05x | - | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Silo Pharma Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 2.18K | 0.03 | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on Jun 3, 2026.
Who owns Silo Pharma Inc
- Insiders 7.64%
- Institutions 13.60%
- Public & others 78.76%
- Shares outstanding 2.16M
- Free float 1.58M
Top funds holding SILO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 96.1K | 4.36% | 0.00% | Oct 2026 |
| Fidelity Extended Market Index | 8.57K | 0.39% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.18K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 260.00 | 0.01% | 0.00% | Sep 2026 |
Top institutions holding SILO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 75.6K | 8.51% | +70.74% | Jun 2026 |
| Renaissance Technologies Corp | 23.5K | 2.65% | 0.00% | Sep 2026 |
| Citadel Advisors Llc | 16.8K | 1.89% | +1,074.83% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.0K | 1.35% | +1,498.40% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 874.00 | 0.10% | +0.11% | Jun 2026 |
| Tower Research Capital LLC | 181.00 | 0.02% | +61.61% | Jun 2026 |
| IFP Advisors, LLC | 175.00 | 0.02% | +1,358.33% | Jun 2026 |
| HARBOUR INVESTMENTS, INC. | 14.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 1.00 | 0.00% | 0.00% | Jun 2026 |
| State Street Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Susquehanna International Group, LLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Jane Street Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| LPL Financial Corp | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Silo Pharma Inc company profile
- Company name
- Silo Pharma Inc
- Ticker
- SILO.US
- Exchange
- USA Stocks
- Listed since
- May 13, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3
- Fiscal year end
- December
- Address
- 677 North Washington Boulevard, Sarasota, FL, United States, 34236
- Phone
- 718 400 9031
- Website
- silopharma.com
About Silo Pharma Inc
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Silo Pharma Inc management
2- Mr. Eric WeisblumChairman, President & CEO · born 1970
- Mr. Daniel E. RyweckChief Financial Officer · born 1965